Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TBE vaccination immunity in allogeneic HSCT recipients
2011-002928-41Phase 2Completed
- Sponsor
- Medical University of Vienna, Department of Internal Medicine I
- Start
- Nov 2012
- Modality
- Whole Inactivated Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of FSME-IMMUN in tick-borne encephalitis (TBE) (2 arms), sponsored by Medical University of Vienna, Department of Internal Medicine I. Primary endpoint: Seroconversion by neutralization test after second vaccination. Started Nov 2012; status: completed.
02
Drugs
FSME-IMMUN
03
Conditions
tick-borne encephalitis (TBE)
Beyond the preview
Go deeper on 2011-002928-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-002928-41.